Salvage radiotherapy in previously operated recurrent cervical cancer


ŞAHİNLER İ. , Uzel Ö., Tuncer T., Tabak S., Atkovar G., Okkan S.

Journal of B.U.ON., cilt.6, sa.1, ss.37-41, 2001 (SCI Expanded İndekslerine Giren Dergi) identifier

  • Cilt numarası: 6 Konu: 1
  • Basım Tarihi: 2001
  • Dergi Adı: Journal of B.U.ON.
  • Sayfa Sayıları: ss.37-41

Özet

Purpose: To assess the efficacy of radiotherapy and the significance of some prognostic factors in previously operated recurrent cervical cancer patients. Patients and methods: Between 1978-1998, 39 patients with previously operated cervical cancer (34 squamous cell carcinomas and 5 adenocarcinomas) with recurrent disease received salvage radiation therapy. Thirty-eight patients received external pelvic irradiation up to 50-56 Gy. In order to increase the total dose, intracavitary radiotherapy (n=26, 16-30 Gy), interstitial radiotherapy (n=2, 14 and 40 Gy, respectively), and external boost radiotherapy (n=10, 14-20 Gy) were also delivered. One patient was treated by intracavitary radiotherapy alone (68 Gy). Results: The median patients' age was 50 years (range 31-70 years). The median time to recurrence was 11 months (range 2-70 months). The median follow-up time was 19.5 months (range 2-120 months). Pelvic control and overall survival rates at 5 years were 43.3% and 37.5%, respectively. Histology, tumor size (≤4 cm versus >4 cm), localization of recurrent disease, time to recurrence (≤ 1 year versus >1 year) and type of operation were evaluated as prognostic factors in univariate analysis, in which only histology showed statistical significance in terms of disease-free and overall survival (p=0.01). Histology (p=0.008) and time to recurrence (p=0.007) were significant prognostic factors in the multivariate analysis for overall survival. Late complications were observed in 7 patients. Conclusion: Tumor histology and time to recurrence were prognostic factors that significantly influenced the overall survival. Our findings show that radiotherapy is the treatment of choice for recurrent cervical cancer.